Volume 9, Issue 3, July 2019

Formulation Development and Evaluation of Tenofovir Disoproxil Fumarate Controlled Release Tablets

Author(s): Leelakrishna Chowdary Anumolu* and Ankamma Chowdary Yarlagadda
Abstract: Tenofovir is a nucleoside reverse-transcriptase inhibitor that is currently being investigated as a potential HIV microbicide candidate, with a recent phase IIb study of a 1% (w/w) tenofovir gel reducing HIV acquisition by 39% in sexually active women. Tenofovir is nucleotide analogue reverse transcriptase inhibitors (nRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. Tenofovir disoproxil fumarate (a prodrug of tenofovir) film coated tablets contain 150 mg, 200 mg, 250 mg, and 300 mg of tenofovir disoproxil fumarate, distributed by Gilead Sciences with trademark of VIREAD. The objective of present investigation was to formulate and evaluate the controlled release tablets of Tenofovir using high molecular weight water-soluble poly (ethylene oxide) polymers and natural gums like Guar gum, Gum Kondagogu. A combination of natural hydrophilic polymers with synthetic hydrophilic polymers like poly (ethylene oxide) was also used in the preparation of matrix tablets and evaluated for their influence on controlled drug release. Matrix tablets were prepared by direct compression method using Tenofovir Solid dispersion as an active component which was prepared by solvent evaporation method using carrier poloxamer P188(in the ratio of 1:2). The matrix tablets were evaluated for hardness, weight variation, friability and for in-vitro release of the drug. The tablets containing Polyox-WSR 303 (TF6 with drug: polymer ratio 1:1.5) and combination of natural polymer gum kondagogu and Polyox-WSR 303 (TF9 with drug: polymer ratio 1:1.5) exhibited controlled release for a prolonged period of time. All the physical characteristics evaluated for the tablets were found to be within the acceptable limits.
PAGES: 143-151  |  28 VIEWS  32 DOWNLOADS

How To Cite this Article:

Leelakrishna Chowdary Anumolu* and Ankamma Chowdary Yarlagadda. Formulation Development and Evaluation of Tenofovir Disoproxil Fumarate Controlled Release Tablets. 2019; 9(3): 143-151.